Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,500.0 million
Deal Type : Acquisition
Roche to Complete $1.5 Billion Acquisition of U.S. Biopharma Company Poseida
Details : The acquisition enhances Roche’s pipeline with therapies in oncology, immunology, and neurology, including P-BCMA-ALLO1, an allogeneic CAR-T, entering donor-derived off-the-shelf cell therapies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $1,500.0 million
January 08, 2025
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,500.0 million
Deal Type : Acquisition
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,500.0 million
Deal Type : Acquisition
Roche Acquires Poseida for Cell Therapy Candidates and Platform Technologies
Details : The acquisition enhances Roche’s pipeline with therapies in oncology, immunology, and neurology, including P-BCMA-ALLO1, an allogeneic CAR-T, entering donor-derived off-the-shelf cell therapies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $1,500.0 million
November 26, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,500.0 million
Deal Type : Acquisition
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Poseida Reports Positive Interim Results For CAR-T Therapy in Myeloma
Details : P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Poseida Wins RMAT Designation from FDA for Multiple Myeloma Therapy P-BCMA-ALLO1
Details : P-BCMA-ALLO1 is a RMAT designated novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen for the treatment of relapsed/refractory multiple myeloma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 16, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Poseida Receives FDA Orphan Drug Designation for P-BCMA-ALLO1 in Multiple Myeloma
Details : P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bellicum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bellicum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-MUC1C-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Astellas Pharma
Deal Size : $50.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Astellas gains a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs, P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 08, 2023
Lead Product(s) : P-MUC1C-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Astellas Pharma
Deal Size : $50.0 million
Deal Type : Licensing Agreement
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Details : BPX-601 incorporates high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA). It is being discontinued following the company’s assessment of BPX-601 risk/benefit profile in combinati...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BPX-601 is our first clinical candidate incorporating our high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA).
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : BPX-601,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $6,220.0 million
Deal Type : Collaboration
Details : Under the agreement with Poseida, Roche to develop allogeneic CAR-T cell therapies for hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T cell product to treat multiple myeloma, and P-CD19CD20-ALLO1 to treat B cell malignancies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $110.0 million
March 08, 2022
Lead Product(s) : P-BCMA-ALLO1,Rimiducid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $6,220.0 million
Deal Type : Collaboration